Favorable Long-Term Results With Ranibizumab Implant for Neovascular AMD
The ranibizumab port delivery system (PDS; Susvimo) with 6-month refill maintained noninferiority to monthly intravitreal injections for neovascular age-related macular degeneration (nAMD) out to 2 years, according to updated results from a randomized trial. Three assessments of best corrected visual acuity (BCVA) during years 1 to 2 showed differences ranging from -0.2 to +0.4 ETDRS […]